Table 1 Baseline patient demographics and clinicopathological characteristics (n = 318)
Baseline variables | 2000–2010 (n = 183) | 2011–2016 (n = 135) | p value |
|---|---|---|---|
Age at resection, years | |||
Median (IQR) | 60.2 (52.2–67.8) | 62.6 (55.7–68.3) | 0.1354 |
Sex | |||
% males | 105/183 (57.4%) | 82/135 (60.7%) | 0.3629 |
ASA score | |||
% 3 or 4 | 36/183 (19.7%) | 25/135 (18.5%) | 0.7962 |
CEA, ng/ml | |||
% with ≥ 200 ng/ml | 16/178 (9.0%) | 10/130 (7.7%) | 0.6861 |
Primary tumour grade (poor vs well or moderate) | |||
% poor | 10/176 (5.7%) | 4/120 (3.33%) | 0.3500 |
pTumour stage | |||
% 3 or 4 | 169/183 (92.4%) | 124/135 (91.9%) | 0.8705 |
pNode stage | |||
% 1 or 2 | 142/183 (77.6%) | 86/135 (63.7%) | 0.0066 |
Primary tumour (colon vs rectal) | |||
% colon | 140/183 (76.5%) | 109/135 (80.7%) | 0.3648 |
Largest liver metastases | |||
% ≥ 5 cm diameter | 37/182 (20.3%) | 18/130 (13.9%) | 0.1384 |
Distribution of liver metastases (bilobar vs unilobar) | |||
% bilobar | 43/183 (23.5%) | 42/133 (31.6%) | 0.1097 |
Multiple vs solitary liver metastases | |||
% multiple metastases | 76/183 (41.5%) | 54/132 (40.9%) | 0.9121 |
Synchronous vs metachronous | |||
% synchronous | 89/183 (48.6%) | 66/135 (48.9%) | 0.964 |
Major vs minor | |||
% major | 96/182 (52.7%) | 59/133 (44.4%) | 0.141 |
Margins (R1/R2 vs R0) | |||
% R0 | 151/183 (82.5%) | 109/134 (81.3%) | 0.789 |
DFI (> 12 months vs ≤ 12 months) | |||
% ≤ 12 months | 132/183 (72.1%) | 97/135 (71.9%) | 0.956 |
Neoadjuvant chemotherapy for liver metastases | |||
% neoadjuvant chemotherapy | 121/183 (66.1%) | 71/134 (53%) | 0.018 |
Adjuvant chemotherapy for liver metastases | |||
% adjuvant chemotherapy | 69/179 (38.5%) | 80/132 (60.6%) | < 0.0001 |
CRS liver score | |||
% with ≥ 3 points | 75/183 (41.0%) | 38/135 (28.2%) | 0.0181 |